The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Which interventions offer best value for money in primary prevention of cardiovascular disease
Open accessAbstract
BACKGROUND: Despite many decades of declining mortality rates in the Western world, cardiovascular disease remains the leading cause of death worldwide. In this research we evaluate the optimal mix of lifestyle, pharmaceutical and population-wide interventions for primary prevention of cardiovascular disease. METHODS AND FINDINGS: In a discrete time Markov model we simulate the ischaemic heart disease and stroke outcomes and cost impacts of intervention over the lifetime of all Australian men and women, aged 35 to 84 years, who have never experienced a heart disease or stroke event. Best value for money is achieved by mandating moderate limits on salt in the manufacture of bread, margarine and cereal. A combination of diuretic, calcium channel blocker, ACE inhibitor and low-cost statin, for everyone with at least 5% five-year risk of cardiovascular disease, is also cost-effective, but lifestyle interventions aiming to change risky dietary and exercise behaviours are extremely poor value for money and have little population health benefit. CONCLUSIONS: There is huge potential for improving efficiency in cardiovascular disease prevention in Australia. A tougher approach from Government to mandating limits on salt in processed foods and reducing excessive statin prices, and a shift away from lifestyle counselling to more efficient absolute risk-based prescription of preventive drugs, could cut health care costs while improving population health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, legislation promoting a healthy lifestyle, such as reduced salt intake and smoking bans, are cost effective in preventing CVD. 18-22”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775 · cited 2×
“Newer evidence on drug efficacy [12,13], including alternative blood pressure-lowering drugs such as calcium channel blockers and ACE inhibitors, the changing price of statins [14–16], and increasing doubts about the use of aspirin in primary prevention [17,18], however, may mean that this is no longer the optimal str…”
BackgroundCardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163 · cited 1×
“We determine the probability of an event using the Framingham risk prediction equation [29].”
MethodMaking choices in health: who guide to cost-effectiveness analysis
(2004) · Revista Española de Salud Pública · doi:10.1590/s1135-57272004000300012 · Cited by 1,259
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232 · cited 2×
“Each cost is estimated as an average across the class, weighted by the mix of scripts provided in 2008 for an equivalent standard dose [38,39] (e.”
BackgroundLaw, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210 · cited 1×
“80% reduction in relative risk of stroke [13,50,51].”
BackgroundBrugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“Newer evidence on drug efficacy [12,13], including alternative blood pressure-lowering drugs such as calcium channel blockers and ACE inhibitors, the changing price of statins [14–16], and increasing doubts about the use of aspirin in primary prevention [17,18], however, may mean that this is no longer the optimal str…”
BackgroundUnal, B., Critchley, J. A., & Capewell, S. (2004) · Circulation · doi:10.1161/01.cir.0000118498.35499.b2 · Cited by 739
Gold, M. R., Stevenson, D., & Fryback, D. G. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140513 · Cited by 652 · cited 1×
“these analyses, we base our results on health gain measured in DALYs, but since there is debate about when QALYs or DALYs are the superior measure [57], we also evaluate cost-effectiveness in QALYs to determine the impact (if any) of the QALY or DALY choice on cost-effectiveness results.”
ResultFowkes, F. G. R. (2010) · JAMA · doi:10.1001/jama.2010.221 · Cited by 624 · cited 2×
“Newer evidence on drug efficacy [12,13], including alternative blood pressure-lowering drugs such as calcium channel blockers and ACE inhibitors, the changing price of statins [14–16], and increasing doubts about the use of aspirin in primary prevention [17,18], however, may mean that this is no longer the optimal str…”
BackgroundEstimates of global and regional potential health gains from reducing multiple major risk factors
Ezzati, M., Vander Hoorn, S., Rodgers, A., Lopez, A. D., Mathers, C. D., & Murray, C. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13968-2 · Cited by 610 · cited 1×
“a statin and a diuretic) are determined multiplicatively [53] (e.”
BackgroundMurray, C. J., Lauer, J. A., Hutubessy, R. C., Niessen, L., Tomijima, N., Rodgers, A., Lawes, C. M., & Evans, D. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12655-4 · Cited by 599 · cited 5×
“Our results are broadly consistent with the results of previous analyses from WHO-CHOICE [11], Argentina [22] and Vietnam PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41842 [21].”
BackgroundResultInfluentialAsaria, P., Chisholm, D., Mathers, C., Ezzati, M., & Beaglehole, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61698-5 · Cited by 572
Multiple risk factor interventions for primary prevention of coronary heart disease
Ebrahim, S., Taylor, F., Ward, K., Beswick, A., Burke, M., & Davey Smith, G. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001561.pub3 · Cited by 546
George, B., Harris, A., & Mitchell, A. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119110-00004 · Cited by 431
Frost, C. D., Law, M. R., & Wald, N. J. (1991) · BMJ · doi:10.1136/bmj.302.6780.815 · Cited by 399
Dietary advice for reducing cardiovascular risk
Brunner, E., Thorogood, M., Rees, K., & Hewitt, G. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002128.pub2 · Cited by 351
Weng, T.-C., Yang, Y.-H. K., Lin, S.-J., & Tai, S.-H. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01085.x · Cited by 345
Law, M. R., Frost, C. D., & Wald, N. J. (1991) · BMJ · doi:10.1136/bmj.302.6780.811 · Cited by 302
Ford, E. S., & Capewell, S. (2011) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031210-101211 · Cited by 300 · cited 1×
“Despite many decades of declining mortality rates in the Western world [1,2], cardiovascular disease (CVD) remains the leading cause of death worldwide [3].”
BackgroundSmith-Spangler, C. M., Juusola, J. L., Enns, E. A., Owens, D. K., & Garber, A. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-8-201004200-00212 · Cited by 244
Begg, S. J., Vos, T., Barker, B., Stanley, L., & Lopez, A. D. (2008) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb01503.x · Cited by 239 · cited 1×
“In countries such as the United States (US), United Kingdom (UK) and Australia, the majority of cardiovascular burden could be prevented by better addressing key risks, such as blood pressure and cholesterol levels [4–6].”
BackgroundSelf-citationAustralia New Zealand Food Standards Code
Winger, R. (2003) · Food Control · doi:10.1016/s0956-7135(03)00044-6 · Cited by 227
Cost-effectiveness of interventions to reduce dietary salt intake
Cobiac, L. J., Vos, T., & Veerman, J. L. (2010) · Heart · doi:10.1136/hrt.2010.199240 · Cited by 223 · cited 1×
“programs are likely to be even more cost-effective [11,21,22] and potentially even cost-saving [23–25].”
BackgroundSelf-citationGeneral practice in Australia 2000
Hindle, D. (2001) · Australian Health Review · doi:10.1071/ah010201 · Cited by 215
Capewell, S., Ford, E. S., Croft, J. B., Critchley, J. A., Greenlund, K. J., & Labarthe, D. R. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.08.057885 · Cited by 200 · cited 1×
“In countries such as the United States (US), United Kingdom (UK) and Australia, the majority of cardiovascular burden could be prevented by better addressing key risks, such as blood pressure and cholesterol levels [4–6].”
BackgroundThrift, A. G., Dewey, H. M., Macdonell, R. A. L., McNeil, J. J., & Donnan, G. A. (2000) · Stroke · doi:10.1161/01.str.31.9.2087 · Cited by 197
Barton, P., Andronis, L., Briggs, A., McPherson, K., & Capewell, S. (2011) · BMJ · doi:10.1136/bmj.d4044 · Cited by 195 · cited 1×
“programs are likely to be even more cost-effective [11,21,22] and potentially even cost-saving [23–25].”
BackgroundDewey, H. M., Thrift, A. G., Mihalopoulos, C., Carter, R., Macdonell, R. A. L., McNeil, J. J., & Donnan, G. A. (2001) · Stroke · doi:10.1161/hs1001.097222 · Cited by 184
Self-citationImpact of the Pick the Tick food information programme on the salt content of food in New Zealand
Young, L. (2002) · Health Promotion International · doi:10.1093/heapro/17.1.13 · Cited by 178 · cited 2×
“The cost of the current voluntary program for salt reduction in breads, margarines and cereals is derived from the proportion of products participating in the current Heart Foundation program [45] and the annual fee per product (C.”
BackgroundMethodDietary advice for reducing cardiovascular risk
Brunner, E. J., Rees, K., Ward, K. J., Burke, M., & Thorogood, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002128.pub3 · Cited by 165 · cited 1×
“2%) [47,76]”
Putting prevention first - vascular checks: risk assessment and management
Young, H. (2010) · Cited by 160
Multiple risk factor interventions for primary prevention of coronary heart disease
Ebrahim, S. B. J., Beswick, A. D., Burke, M., & Smith, G. D. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001561.pub2 · Cited by 156
Heeley, E. L., Peiris, D., Patel, A. A., Cass, A., Weekes, A., Morgan, C. L., Anderson, C. S., & Chalmers, J. P. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03502.x · Cited by 145 · cited 1×
“Australian GPs have been slow to adopt tools for absolute risk assessment [69] with prescribing still largely guided by a confusing mix of rules and criteria defining thresholds for treatment of high blood pressure and cholesterol.”
BackgroundFerket, B. S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.434 · Cited by 134 · cited 1×
“Most guidelines recommend lifestyle behaviour-change approaches as a first line strategy, with blood pressure-lowering and/or cholesterol drugs for those at highest risk [7].”
BackgroundMeta‐Analysis of Natural Therapies for Hyperlipidemia: Plant Sterols and Stanols versus Policosanol
Chen, J. T., WESLEY, R. A., Shamburek, R. D., Pucino, F., & Csákó, G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.2.171.56942 · Cited by 132 · cited 1×
“4 g of plant sterols are required each day to achieve a beneficial effect [43].”
BackgroundCommunity Programs for the Prevention of Cardiovascular Disease: A Systematic Review
Pennant, M., Davenport, C., Bayliss, S., Greenheld, W., Marshall, T., & Hyde, C. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq171 · Cited by 131
(2010) · Cited by 121
Self-citationRubinstein, A., Colantonio, L. D., Bardach, A., Caporale, J., Martí, S. G., Kopitowski, K. S., Alcaraz, A. O., Gibbons, L., Augustovski, F., & Pichón-Rivière, A. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-627 · Cited by 119 · cited 4×
“Although this has not been compared with the costeffectiveness of population-wide strategies, analyses from WHOCHOICE, Argentina, Vietnam, the UK, US and Australia, have found that population-wide strategies, particularly salt reduction PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41842 programs are…”
BackgroundResultInfluentialWells, S., Furness, S., Rafter, N., Horn, E., Whittaker, R., Stewart, A., Moodabe, K., Roseman, P., Selak, V., Bramley, D., et al. (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3282f13af4 · Cited by 109 · cited 1×
“Web-based tools that integrate cardiovascular absolute risk assessment with electronic medical record systems may also be of benefit [70].”
BackgroundCholesterol-Lowering Interventions and Stroke
Caterina, R. D., Scarano, M., Marfisi, R., Lucisano, G., Palma, F., Tatasciore, A., & Marchioli, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.062 · Cited by 98 · cited 1×
“80% reduction in relative risk of stroke [13,50,51].”
BackgroundAssessing cost-effectiveness in prevention : ACE–prevention September 2010 final report
Vos, T., Carter, R., Barendregt, J. J., Mihalopoulos, C., Veerman, L. J., Magnus, A., Cobiac, L. J., Bertram, M., & Wallace, A. (2010) · Deakin Research Online (Deakin University) · Cited by 83
Self-citationPersistence with antihypertensive medication: Australia‐wide experience, 2004–2006
Simons, L. A., Ortiz, M. S., & Calcino, G. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb01589.x · Cited by 72
Effective population-wide public health interventions to promote sodium reduction
Mohan, S., Campbell, N. R. C., & Willis, K. J. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090361 · Cited by 65 · cited 1×
“Some countries have also implemented community- or population-wide interventions; many community-level heart health programs were run between the 1970s and 1990s [9], and countries, such as Finland and the UK, have also established long-term programs to reduce population dietary salt levels [10].”
BackgroundCost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam
Ha, D. A., & Chisholm, D. (2011) · Health Policy and Planning · doi:10.1093/heapol/czq045 · Cited by 65 · cited 1×
“programs are likely to be even more cost-effective [11,21,22] and potentially even cost-saving [23–25].”
BackgroundMoon, J., & Bogle, R. (2006) · BMJ · doi:10.1136/bmj.332.7554.1344 · Cited by 57
Discontinuation rates for use of statins are high
Simons, L. A., Simons, J., McManus, P., & Dudley, J. (2000) · BMJ · doi:10.1136/bmj.321.7268.1084 · Cited by 52 · cited 1×
“Of those patients eligible to receive intervention, we assume that 40% will no longer be adherent after 12 months, based on rates of discontinuation with blood pressure-lowering and cholesterollowering therapies in Australia [35,36].”
BackgroundÜnal, B., Critchley, J., & Capewell, S. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.09.015 · Cited by 46 · cited 1×
“In countries such as the United States (US), United Kingdom (UK) and Australia, the majority of cardiovascular burden could be prevented by better addressing key risks, such as blood pressure and cholesterol levels [4–6].”
BackgroundDon't use aspirin for primary prevention of cardiovascular disease
Barnett, H., Burrill, P. D., & Iheanacho, I. (2010) · BMJ · doi:10.1136/bmj.c1805 · Cited by 45 · cited 1×
“Newer evidence on drug efficacy [12,13], including alternative blood pressure-lowering drugs such as calcium channel blockers and ACE inhibitors, the changing price of statins [14–16], and increasing doubts about the use of aspirin in primary prevention [17,18], however, may mean that this is no longer the optimal str…”
BackgroundExpiry of patent protection on statins: effects on pharmaceutical expenditure in Australia
Clarke, P., & Fitzgerald, E. M. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03661.x · Cited by 43
Life after statin patent expiries
Kidd, J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2156 · Cited by 34 · cited 1×
“Newer evidence on drug efficacy [12,13], including alternative blood pressure-lowering drugs such as calcium channel blockers and ACE inhibitors, the changing price of statins [14–16], and increasing doubts about the use of aspirin in primary prevention [17,18], however, may mean that this is no longer the optimal str…”
BackgroundCosts of the 'Hartslag Limburg' community heart health intervention
Ronckers, E. T., Groot, W. N. J., Steenbakkers, M. W. H. L., Ruland, E., & Ament, A. J. H. A. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-51 · Cited by 26
An alternative approach to projecting health expenditure in Australia
Begg, S. J., Vos, T., Goss, J. R., & Mann, N. (2008) · Australian Health Review · doi:10.1071/ah080148 · Cited by 25 · cited 1×
“Trends are incorporated to capture underlying changes in IHD and stroke incidence and case fatality over time [56].”
BackgroundSelf-citationThe WHO MONICA study, Australia, 1984-1993: A summary of the Newcastle and Perth MONICA Projects
McElduff, P., Dobson, A. J., Jamrozik, K. D., & HOBBS, M. S. T. (2000) · UWA Profiles and Research Repository (UWA) · Cited by 16
General practitioner services in Australia
Burgess, T. C., & Beilby, J. (2005) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 9
New direct thrombin inhibitor becomes available
Thompson, C. A. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/news100027 · Cited by 3
Turnbull, F., Arima, H., Heeley, E. L., Peiris, D., Weekes, A., Morgan, C., Cass, A., Anderson, C. S., Patel, A. A., & Chalmers, J. P. (2009) · Heart Lung and Circulation · doi:10.1016/j.hlc.2009.05.669 · Cited by 1
Research works printed but not linked: 1
- S Lim, 2005, Priority setting for the primary prevention of coronary heart disease and stroke in Australia [PhD thesis].
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Metadata
- Authors
- Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T.
- Affiliations
- The University of Queensland (AU)
- Deakin University (AU)
- Institute for Health Metrics and Evaluation (US)
- Corresponding author
- Cobiac, Linda J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-23
- Volume
- 7
- Issue
- 7
- Pages
- e41842
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3402472
- OpenAlex
- W2010609873
- Cited by
- 97
- References
- 60
- Citations by year
- 2025: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 8 · 2018: 5 · 2017: 16 · 2016: 14 · 2015: 11 · 2014: 11 · 2013: 7 · 2012: 3
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Griffith Research Online (submittedVersion, cc-by)
- Funders
- Medical Research Council
- National Health and Medical Research Council (351558)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- cardiovascular disease prevention, primary prevention, cost-effectiveness, statins, lifestyle intervention, ischemic heart disease, stroke, diuretics, calcium channel blockers, ACE inhibitors, health care costs, Australia
- MeSH terms
- Adult, Aged, Aged, 80 and over, Blood Pressure, Cardiovascular Diseases, Cholesterol, Cost-Benefit Analysis, Female, Humans, Life Style, Male, Middle Aged, Primary Prevention, Health Care Sector
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.